ProPhase Labs, Inc. Disposal Group, Including Discontinued Operation, Costs of Goods Sold
ProPhase Labs, Inc. (PRPH) reported Disposal Group, Including Discontinued Operation, Costs of Goods Sold of $2.04 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold · last filed 2019-03-26
- ProPhase Labs, Inc. disposal group, including discontinued operation, costs of goods sold for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. disposal group, including discontinued operation, costs of goods sold for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. disposal group, including discontinued operation, costs of goods sold for the quarter ending 2017-06-30 was $264.00K, a 63.74% decline year-over-year.
- ProPhase Labs, Inc. disposal group, including discontinued operation, costs of goods sold for the quarter ending 2017-03-31 was $1.77M, a 4.36% increase year-over-year.
- ProPhase Labs, Inc. disposal group, including discontinued operation, costs of goods sold for fiscal 2017 was $2.04M, a 73.68% decline from fiscal 2016.
- ProPhase Labs, Inc. disposal group, including discontinued operation, costs of goods sold for fiscal 2016 was $7.74M, a 14.79% increase from fiscal 2015.
- ProPhase Labs, Inc. disposal group, including discontinued operation, costs of goods sold for fiscal 2015 was $6.74M.
| Period end | Disposal Group, Including Discontinued Operation, Costs of Goods Sold 3 month | Disposal Group, Including Discontinued Operation, Costs of Goods Sold 6 month | Disposal Group, Including Discontinued Operation, Costs of Goods Sold 9 month | Disposal Group, Including Discontinued Operation, Costs of Goods Sold 12 month | Disposal Group, Including Discontinued Operation, Costs of Goods Sold 12 month as first filed |
|---|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $0.00 derived: sum of 2 quarters · filed 2019-03-26 | $264.00K derived: sum of 3 quarters · filed 2019-03-26 | $2.04M 10-K · filed 2019-03-26 | $2.04M 10-K · filed 2018-03-28 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2018-11-14 | $264.00K derived: sum of 2 quarters · filed 2018-11-14 | $2.04M 10-Q · filed 2018-11-14 | $5.52M derived: sum of 4 quarters · filed 2018-11-14 | |
| 2017-06-30 | $264.00K 10-Q/A · filed 2018-08-20 | $2.04M 10-Q/A · filed 2018-08-20 | $5.52M derived: sum of 3 quarters · filed 2018-08-20 | $7.35M derived: sum of 4 quarters · filed 2018-08-20 | |
| 2017-03-31 | $1.77M 10-Q/A · filed 2018-08-20 | $5.26M derived: sum of 2 quarters · filed 2018-08-20 | $7.08M derived: sum of 3 quarters · filed 2018-08-20 | $7.81M derived: sum of 4 quarters · filed 2018-08-20 | |
| 2016-12-31 | $3.48M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2018-08-20 | $5.31M derived: sum of 2 quarters · filed 2018-08-20 | $6.04M derived: sum of 3 quarters · filed 2018-08-20 | $7.74M 10-K/A · filed 2018-08-20 | |
| 2016-09-30 | $1.83M 10-Q/A · filed 2018-08-20 | $2.56M derived: sum of 2 quarters · filed 2018-08-20 | $4.25M 10-Q/A · filed 2018-08-20 | ||
| 2016-06-30 | $728.00K 10-Q/A · filed 2018-08-20 | $2.43M 10-Q/A · filed 2018-08-20 | |||
| 2016-03-31 | $1.70M 10-Q/A · filed 2018-08-20 | ||||
| 2015-12-31 | $6.74M 10-K/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |